In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...

Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

Like recombinant DNA before it, gene editing has the potential to transform medicine, agriculture and more. CRISPR is now used by thousands of biologists in labs across the globe. A revolution in food ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

Hundreds of children with severe epilepsy will be able to benefit from a groundbreaking new treatment on the NHS that could significantly reduce their seizures, providing new hope for them and their ...

An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.